Amgen

News

Ex-Merck R&D chief Perlmutter takes reins at drug discovery ...

A new drug discovery firm, Eikon Therapeutics, has launched with former Merck & Co research chief Roger Perlmutter at the helm.

News

BMS' deucravacitinib psoriasis pill could launch next year a...

Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.

News

Amgen buys inflammatory diseases drug firm Rodeo for up to $...

Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its potential tissue repair drugs in a deal worth up to $721 million.

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Amgen in $1.9bn swoop for Five Prime and its gastric cancer ...

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline.

News

AZ trumpets tezepelumab data as filing for severe asthma loo...

AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half of this year, with a broader indication than riv

Ex-Merck R&D chief Perlmutter takes reins at drug discovery ...

BMS' deucravacitinib psoriasis pill could launch next year a...

Boehringer and MD Anderson extend KRAS cancer collaboration

Amgen buys inflammatory diseases drug firm Rodeo for up to $...

Amgen in $1.9bn swoop for Five Prime and its gastric cancer ...

AZ trumpets tezepelumab data as filing for severe asthma loo...

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

Amgen

Editor's Picks